Share Name Share Symbol Market Type Share ISIN Share Description
Premaitha LSE:NIPT London Ordinary Share GB00BN31ZD89 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25p +3.08% 8.375p 8.00p 8.75p 8.375p 8.00p 8.125p 631,238.00 16:26:53
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 2.5 -12.1 6.0 1.4 19.11

Premaitha (NIPT) Latest News

More Premaitha News
Premaitha Takeover Rumours

Premaitha (NIPT) Share Charts

1 Year Premaitha Chart

1 Year Premaitha Chart

1 Month Premaitha Chart

1 Month Premaitha Chart

Intraday Premaitha Chart

Intraday Premaitha Chart

Premaitha (NIPT) Discussions and Chat

Premaitha (NIPT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Premaitha trades in real-time

Premaitha (NIPT) Top Chat Posts

DateSubject
03/12/2016
08:20
Premaitha Daily Update: Premaitha is listed in the Software & Computer Services sector of the London Stock Exchange with ticker NIPT. The last closing price for Premaitha was 8.13p.
Premaitha has a 4 week average price of 8.49p and a 12 week average price of 9.48p.
The 1 year high share price is 21.50p while the 1 year low share price is currently 7.38p.
There are currently 228,163,709 shares in issue and the average daily traded volume is 239,096 shares. The market capitalisation of Premaitha is £19,108,710.63.
01/11/2016
18:14
dire cons: Previously on 10/27/2016, finnCap reported on Premaitha Health Plc (LON:NIPT) held steady the target price at 20.00GBX. finnCap on Monday reiterated Premaitha Health Plc's analyst rating as "Corporate" with its price target of 20 highlighting a potential increase of 110.97% from Premaitha Health Plc's current price of 9.48. The average stock price target is 22.00GBX with 0 brokers rating the stock a strong buy, 1 broker rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell. The company has a 50 day moving average price of GBX 10.00 and a 200 day moving average price of GBX 9.54. There are now 228,163,000 shares in issue with a current share value of 10.12 giving Premaitha Health a market capitalisation of 23.08M GBp. The 52 week high for the share price is 21.5 while the 52 week low for the stock is 6.5. AIM-listed molecular diagnostics company Premaitha Health, a developer of a prenatal screening system, said on Friday it welcomed the decision by the Department of Health to make non-invasive prenatal tests routinely available on the NHS to high risk pregnant women. The Company's techniques are used for pre-natal screening (NIPT) and other clinical applications in the early detection, monitoring and treatment of disease. The National Screening Committee's recommended in January that non-invasive prenatal tests should be freely available on the NHS, as part of the foetal anomaly screening programme to women with a higher risk of their baby developing Down's, Edwards' or Patau's syndrome. The analysis is performed on cell-free placental deoxyribonucleic acid (DNA) from a maternal blood sample, with test results available in three days turnaround time.
31/10/2016
07:34
sherlock2020: Good news today, and an even better share price at which to get in. Just checking to see if my last SIPP payment has cleared yet ....
27/10/2016
07:23
twix386: if you have a graph of the share price and memory of past expectations. You are looking at them upside down!lol I am not disagreeing with the point you make. I am simply saying today's RNS was issued ONLY because of the AGM, to illicit a smoother meeting. It was non-material and a weak bribe. Plus an obvious bribe, the promise given of contracts to come is not rocket science and they have missed many such promises/expectations before. There is a reason we are sat at 9p and have a graph that looks like that when held the right way up.
20/10/2016
07:23
whites123: MAYA: Mayair Close to £5,500.000 still to spend on share buy back program. Averaged out that equates to over £1.40 per share, but all those bought lower means the upper price to pay can well exceed that marker. Tripling of the share price is easy once stock is in demand. Its a squeeze of epic proportions in the waiting. And yet another RNS from MAYA showing a further share buy back. Each and every time the rns comes out the price increases. Yesterday just 2 purchases. 1 from a PI buying 2,500 shares and the other purchase was a share buy back by the company. They have the mandate to buy approx a further 4 MILLION shares back. The share price will explode... Anyone else here excited about MAYA? (Mayair) They want to buy back 4,247,500 shares (10%) for a maximum of £5,755,750 They have already bought back 340,000 shares for £205,611 So they still have to buy back 3,907,500 shares with £5,550,139 They can pay up to 142p (£5,550,139 / 3,907,500) to acquire the outstanding stock but for every share they buy below 142p, they can pay more than 142p to complete the buy-back, so the price should keep stepping up. The objective of the buy back seems to be to get the share price up. This could triple from here. 19th Oct -2016 RNS today showing they bought back more shares.. In a lightly traded stock like this they have the mandate to buy back almost 4,000,000 more. Where will the share price be by then? Many many multiples of todays price is my best guess.
02/8/2016
12:35
ngen yap: I think the AIM rules states that you release RNS that are share price sensitive. Having announced contract wins and distribution deals previously, and share price not reacting, and clients being sued instead, I reckon management have taken a pragmatic approach in RNS being issued on every tender / deal won. They are clearly winning and more clinics / labs / health institutions are offering IONA (even in places where competitor offering are still on the list). This is being made public in their website. Interesting win on the Bath Hospital. Thanks for info Dave444 - I don't think it equates to 262 tests. The per test price may be between £250 - £350, but I imagine Premaitha may sell it to customers at say £100 - £150 to allow them to make a margin off it. And where it is a distribution deal eg Genoma, take a cut off their sales. So that's works out closer to 436 - 655 tests, which makes sense for start..... If we are doing that and more across our 42 units (and growing), we are doing well. Guess the proof in the pudding will be business results update in due course. Let's see.......
02/8/2016
06:56
twix386: says the guy (DC) who sold out without a word and just told us he'd bought back in when the risk/reward had improved i.e. the share price had sunk even further! Look, I do expect sales numbers to be good. That they once would have been expected much better is I suppose spilt milk now. However, the key is the time we have been in the market versus the share price which is the arbiter of visible and material progress. To be sat at the float price or below for thislong and at this stage just makes it unacceptable to call this anything less than dismal to date. Try answering some of the questions DC. Why no international news outside EU - other than perhaps Vietnam via website - and why not RNS this news if it's worthy of mention and free from Illumina scope? Nothing material delivered anywhere this financial years because if so, it must be RNS'd? and with a year's delay to writ and no contracts/not being reported (RNS), the BOD have created the unfolding share price saga themselves. What other outcome can there be to no visible progress and increasing timeframes whilst under a writ? You gave up and sold out DC and have a nerve after buying back lower to preach about any loss of faith or comment based on lack of newsflow and share price levels once unimagineable lasting months and on-going! Even our 20p target is a mere shadow of the promise I refered to. I actually expect we are doing okay, but it's difficult to know isn't it and a snapshot(share price) this last quarter and for sometime I would expect (pre-writ) and with certain questions remaining isn't a good or transparent backdrop.
02/8/2016
02:40
twix386: Bionet have no mention of us anywhere. They do mention and push and link to Natera's Panorama NIPT test. imv you are over estimating everything again including the numbers game and as we know any material contract win/news that is market sensitive MUST be rns'd. Why with Vietnam, can we not mention it when out of illumina's reach? By Sept we will have had 6 months of commercial contract silence at this rate! The whole financial year to date and what's that done for the share price and sentiment! It's not rocket science to forecast that when the decision was taken to delay the court hearing by a year and to also go Radio Silent, Then the share price was going to crater. This has been a price we have in part inflicted on ourselves as a price worth paying, but it was a silent plan we got to learn of as it unfolded over months and the share price sank, whilst all we were told was the delay was welcomed to increase our commercial momentum! Meanwhile there has been no material news as they must RNS anything market sensitive and frankly SL's said a lot about promise, yet so far delivered a lot less than promised!!
22/4/2016
18:09
blackss: The share price has to be based on a PE of the companies worth, admittedly this company is based on its possible worth but while this might peak at say 30p its unlikely you could sell many at 30p unless that was a good valuation of the company. This is why shares were sold at 6p when the share price is near 11p. and why its not 30p still.. To that end the share price is pretty meaningless and is driven by market makers making a market, try and sell a quantity and see what happens....which is exactly what twix was saying, the share price was driven down by a seller very quickly despite the fundamentals of the company being unchanged. that is also why this has held up at 10p because thats what its worth at the moment and was worth, even when the share price was 30p.
11/3/2016
17:44
rec0very stock: Only have only had a quick look at this so far and need to do more digging. The big risk is the court case. It is likely to drag on and on and suck up cash. The company seems to be well funded for now and recent deals with India and Russia could boost revenues significantly and rapidly. However sadly with medical things, just because something is good does not mean it will automatically get used. Having a large shareholder dribbling out stock on the sly until arrangements are made to take the shares on block could be the explanation for why the share price has fallen on what seems to be very good news. The 8p price is more a reflection on the desperation of the seller and if we believe the explanation, given by Tom W in his own inimitable style “The guy is a tool – who needs to fund other ventures and this is his only liquid counter”. Then he would have driven the share price well below 8p with his dribbling. So it is a good move for all to take his stock on block. and explains the appointment of a joint broker when there seemed no obvious need to waste money on such an extravagance. The whole episode has clearly knocked market confidence, and there in lies the opportunity. Putting the court case risk aside for now this looks to me to be the perfect opportunity to buy for recovery from the effects of Lywood and for the longer term growth that the new markets could bring. Not without risk of course, but nothing ever is, at least they have a proven good product which people do want to buy, so many of these biotech wonders do not even have that. Bringing the court case risk back into the picture definitely clouds the investment case badly. The on going costs are a certainty and even if they win there is no certainty of recovering them. I need to do more digging, but at first site it does look like NIPT have a strong case and are just being bullied by a bigger player. Ultimately my guess is that as long as NIPT can stand up to the bullying in the form of stacking the table with more and more chips in terms of legal costs, eventually there will be an out of court settlement of some kind. If they have built up a good market in India and Russia and they lose the case, then whilst it would be a massive hammer blow, it may not be total wipeout. I am strongly considering a small punt here, no more than 0.5% of the portfolio, but there could be a relatively quick bounce back to 20p and if things work out for the longer term, it could be a reward that makes the risk well worth it.
13/4/2015
12:24
the prophet: timmbo I agree with BlackSS, forget it, as it ain't going to add anything to £55m or whatever market cap NIPT. VIY didn't actually go bust, which was just as well, as it enabled Adam Reynolds to use VIY as a cash shell, but I know what you mean, BlackSS. For info, I think the IP is due to be returned to NIPT any day now, may even have happened. The focus is now clearly on NIPT, if there was any value in the IP, I'm sure Mr Reynolds will do what he can. imo, if we got £0.5m for it, that would be a bloody miracle. That would add, what, 0.25p onto the NIPT share price. That puts it in perspective! Move on is the best course of action, imo.
Premaitha share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20161203 21:49:31